BAY 1101042

Drug Profile

BAY 1101042

Alternative Names: BAY1101042

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 18 Aug 2017 Bayer plans a phase I trial in Healthy volunteers in Germany (NCT03252002)
  • 08 Aug 2017 Preclinical trials in Undefined indication in Germany before August 2017 (PO)
  • 08 Aug 2017 Bayer plans a phase I trial in Healthy volunteers in Germany(NCT03235076)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top